Insilico's Lung Drug Reverses Aging Markers in Study
· Business · Bloomberg
Insilico Medicine has identified a drug candidate that demonstrated the ability to reverse specific markers of aging in preclinical trials. The research focused on targeting biological pathways associated with cellular senescence and age-related decline. Scientists observed that the molecule successfully improved tissue function in animal models during the study. The company is now evaluating the potential for human clinical trials to determine safety and efficacy.
Why it matters
This development represents a potential shift in geriatric medicine by moving from treating individual age-related diseases to targeting the fundamental biological processes of aging itself.
Read the original report — Bloomberg
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.